Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cadence Cancer Center at Delnor
mi
from
Geneva, IL
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cadence Cancer Center at Delnor
mi
from
Geneva, IL
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Loyola University Medical Center
mi
from
Maywood, IL
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cadence Cancer Center in Warrenville
mi
from
Warrenville, IL
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cadence Cancer Center in Warrenville
mi
from
Warrenville, IL
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Franciscan St. Francis Health-Beech Grove
mi
from
Beech Grove, IN
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Franciscan St. Francis Health-Beech Grove
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Franciscan Saint Francis Health-Indianapolis
mi
from
Indianapolis, IN
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Franciscan Saint Francis Health-Indianapolis
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Hutchinson Regional Medical Center
mi
from
Hutchinson, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Hutchinson Regional Medical Center
mi
from
Hutchinson, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
University of Kansas Cancer Center - West
mi
from
Kansas City, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
University of Kansas Cancer Center - West
mi
from
Kansas City, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
University of Kansas Cancer Center
mi
from
Kansas City, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
University of Kansas Cancer Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Center of Kansas - Main Office
mi
from
Wichita, KA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Center of Kansas - Main Office
mi
from
Wichita, KA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Saint Joseph Mercy Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Michigan Cancer Research Consortium CCOP
mi
from
Ann Arbor, MI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Michigan Cancer Research Consortium CCOP
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Spectrum Health Big Rapids Hospital
mi
from
Big Rapids, MI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Spectrum Health Big Rapids Hospital
mi
from
Big Rapids, MI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Oakwood Hospital and Medical Center
mi
from
Dearborn, MI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Oakwood Hospital and Medical Center
mi
from
Dearborn, MI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Mercy Health Saint Mary's
mi
from
Grand Rapids, MI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Mercy Health Saint Mary's
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Mercy Health Mercy Campus
mi
from
Muskegon, MI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Mercy Health Mercy Campus
mi
from
Muskegon, MI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Metro Health Hospital
mi
from
Wyoming, MI
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Metro Health Hospital
mi
from
Wyoming, MI
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Saint Louis University Hospital
mi
from
Saint Louis, MO
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Saint Louis University Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cancer Research for the Ozarks NCORP
mi
from
Springfield, MO
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cox Medical Center South
mi
from
Springfield, MO
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Montana Cancer Consortium NCORP
mi
from
Billings, MT
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Montana Cancer Consortium NCORP
mi
from
Billings, MT
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Frontier Cancer Center and Blood Institute-Billings
mi
from
Billings, MT
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Frontier Cancer Center and Blood Institute-Billings
mi
from
Billings, MT
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Billings Clinic Cancer Center
mi
from
Billings, MT
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Billings Clinic Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Saint Peter's Community Hospital
mi
from
Helena, MT
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Saint Peter's Community Hospital
mi
from
Helena, MT
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Montana Cancer Specialists
mi
from
Missoula, MT
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Montana Cancer Specialists
mi
from
Missoula, MT
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Cone Health Cancer Center
mi
from
Greensboro, NC
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Cone Health Cancer Center
mi
from
Greensboro, NC
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Southeast Cancer Control Consortium CCOP
mi
from
Winston-Salem, NC
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Southeast Cancer Control Consortium CCOP
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Mount Carmel Health Center West
mi
from
Columbus, OH
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Mount Carmel Health Center West
mi
from
Columbus, OH
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Clinton Memorial Hospital
mi
from
Wilmington, OH
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Clinton Memorial Hospital
mi
from
Wilmington, OH
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Baylor Saint Luke's Medical Center
mi
from
Houston, TX
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Baylor Saint Luke's Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Harrison HealthPartners Hematology and Oncology-Bremerton
mi
from
Bremerton, WA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Harrison HealthPartners Hematology and Oncology-Bremerton
mi
from
Bremerton, WA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
EvergreenHealth Medical Center
mi
from
Kirkland, WA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
EvergreenHealth Medical Center
mi
from
Kirkland, WA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Seattle Cancer Care Alliance at EvergreenHealth
mi
from
Kirkland, WA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Seattle Cancer Care Alliance at EvergreenHealth
mi
from
Kirkland, WA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Skagit Valley Hospital
mi
from
Mount Vernon, WA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Skagit Valley Hospital
mi
from
Mount Vernon, WA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Harrison HealthPartners Hematology and Oncology-Poulsbo
mi
from
Poulsbo, WA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Harrison HealthPartners Hematology and Oncology-Poulsbo
mi
from
Poulsbo, WA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Group Health Cooperative of Puget Sound Oncology Consortium
mi
from
Seattle, WA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Group Health Cooperative of Puget Sound Oncology Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Group Health Cooperative-Seattle
mi
from
Seattle, WA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Group Health Cooperative-Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated:  12/14/2015
BCCA-Vancouver Cancer Centre
mi
from
Vancouver,
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Status: Enrolling
Updated: 12/14/2015
BCCA-Vancouver Cancer Centre
mi
from
Vancouver,
Click here to add this to my saved trials
Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)
Nutritional Effect of an Oral Supplement Enriched in Arginine, Glutamine and Leucine Metabolite B-Hydroxy B-Methylbutyrate
Status: Enrolling
Updated:  12/14/2015
Central Arkansas Veterans Healthcare System
mi
from
Little Rock, AR
Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)
Nutritional Effect of an Oral Supplement Enriched in Arginine, Glutamine and Leucine Metabolite B-Hydroxy B-Methylbutyrate
Status: Enrolling
Updated: 12/14/2015
Central Arkansas Veterans Healthcare System
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Birmingham, AL
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials